Intelligent Bio Solutions Inc. (INBS)
NASDAQ: INBS · Real-Time Price · USD
4.190
+0.135 (3.33%)
Mar 9, 2026, 2:32 PM EDT - Market open
Company Description
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally.
The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform.
The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.
Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Intelligent Bio Solutions Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Harry Simeonidis |
Contact Details
Address: 135 West, 41st Street, 5th Floor New York, New York 10036 United States | |
| Phone | 646 828 8258 |
| Website | ibs.inc |
Stock Details
| Ticker Symbol | INBS |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001725430 |
| CUSIP Number | 36151G709 |
| ISIN Number | US36151G7097 |
| Employer ID | 82-1512711 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harry Simeonidis | President and Chief Executive Officer |
| Spiro Kevin Sakiris B.Bus, C.A., Dip Law | Chief Financial Officer |
| Callistus Sequeira | Vice President of Global Quality and Operations |
| Doug Heath | Vice President of Global Sales |
| Anna Turkington | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 8-K | Current Report |
| Feb 12, 2026 | 8-K | Current Report |
| Feb 12, 2026 | 10-Q | Quarterly Report |
| Feb 5, 2026 | 8-K | Current Report |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 21, 2026 | EFFECT | Notice of Effectiveness |
| Jan 21, 2026 | 424B3 | Prospectus |
| Jan 13, 2026 | D | Notice of Exempt Offering of Securities |
| Jan 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 8, 2026 | 8-K | Current Report |